isatori l-carnitine ls3 3000 side effects Liquid LS3® Combining L iSatori L-Carnitine LS3 Concentrated Liquid

These agents include agonists targeting costimulatory receptors such as CD137 (e.g., urelumab or anti-4-1BB/PD-L1 bispecific antibody) [347,348,349,350], CD20 (e.g., rituximab) [351, 352], CD27 (e.g., varlilumab, augments T-cell proliferation) [353, 354], OX40/OX40 ligand [355], CD80 [356], as well as agents like CD40 agonists (e.g., sotigalimab) that enhance antigen presentation by activating DCs and macrophages, which improves antigen presentation and primes a more robust T-cell response [357, 358]

Alternative therapies in health and medicine , 21 Suppl 3 , 2832

10.1038/s41418-017-0012-4 44 GanzT

10.1007/s13105-012-0154-2 17 BoonlaO.KukongviriyapanU.PakdeechoteP.KukongviriyapanV.PannangpetchP.PrachaneyP.et al (2014)